Global Antithrombotic/Anticoagulant Drugs Market Set to Reach $46.2 Billion by 2028 with a 7.9% CAGR

DUBLIN, Nov. 6, 2023 /PRNewswire/ -- The "Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

The global antithrombotic/anticoagulant drugs market is expected to reach $46.2 billion in 2028 from $31.6 billion in 2023 at a CAGR of 7.9%.

This report discusses the implications of the trends mentioned above in the context of the current size and growth of the antithrombotic/anticoagulant drugs market, in global terms and by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the leading drug categories and the country offers breakdowns of the antithrombotic/anticoagulant drugs market.

Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of major players. The patent analysis focuses on technological trends in recent years in regions such as the U.S., Europe, and Japan. The report presents a market analysis and estimates the compound annual growth rate (CAGR) for the antithrombotic/anticoagulant drugs market.

This report segments the global market by these geographic regions: North America, Europe, Asia-Pacific, and the Rest of the World. For market estimates, data are provided for 2022 as the base year, forecasted through 2023-2028.

Companies Mentioned

• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb
• Daiichi Sankyo Co. Ltd.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services Inc.
• Merck & Co. Inc.
• Pfizer Inc.
• Sanofi

Report Includes

• 59 data tables and 35 additional tables
• Overview and an up-to-date analysis of the global markets for antithrombotic/anticoagulant drugs for the treatments of thrombotic (cardiovascular) disease
• Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Examination of the market potential for antithrombotic/anticoagulant drugs, and quantification of the global market for these drugs and its market segments and sub-segments over the next five years
• Estimate of the actual market size and revenue forecast for the market, and corresponding market share analysis based on product type, application and region
• In-depth information (facts and figures) pertaining to the market drivers, challenges, opportunities and prospects, as well as the technologies, regulatory scenarios and impact of COVID-19
• A look at the major vendors in the global market for antithrombotic/anticoagulant drugs, and analysis of the healthcare industry structure, including market shares and recent mergers and acquisitions (M&A) activity
• Review of key patent grants and a look at breakthrough innovations, novel products, upcoming trends and technologies, and emerging applications for cardiovascular treatments
• Insight into the importance of ESG in the worldwide market, with a look at consumer attitudes, risks and opportunities assessment, and ESG practices followed by manufacturers and service providers
• Identification of the major stakeholders, and analysis of the competitive landscape based on recent developments, key financials and segmental revenues, and operational integration
• Profiles of the leading market players

The following are the main conclusions reached in this report regarding antithrombotic and anticoagulant drugs:

• Recent innovations and the emergence of novel thrombin inhibitors have led to the decrease in revenue of traditional anticoagulants such as heparin and Vitamin K antagonists. Low molecular weight heparins, such as Fragmin (-11.8%) and Innohep (-14.1%), have seen a significant decrease in the market.
• The anticoagulant drug market will continue to grow at a slow rate compared to antiplatelet and thrombin inhibitors segment due to the lack of new drug launches since the expiration of the patent on Plavix. The anticoagulant segment is expected to decline soon as prices fall and the market for novel thrombin inhibitors grows.
• The market for thrombin inhibitors is expected to grow at the highest CAGR of 8.1% over the forecast period of 2023 to 2028. Xarelto (rivaroxaban), Eliquis (apixaban), TNKase (tenecteplase) and Savaysa (edoxaban) are the major contributors to the high growth rate of thrombin inhibitors.
• An aging population and the increased prevalence of cardiovascular disease worldwide fueled by a Westernized diet and lifestyle have created new opportunities for antithrombotic/ anticoagulant drug products.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

• Market Outlook
• Market Summary

Chapter 3 Market Overview

• Overview of Cardiovascular Disease
• Coronary Artery Disease
• Atherosclerosis
• Angina (Angina Pectoris)
• Acute Myocardial Infarction
• Medical Management
• Lifestyle Changes
• Diet Modification
• Smoking Cessation
• Pharmaceuticals
• Anticoagulants and Antiplatelet Drugs
• Major Drivers
• Coagulation Factors Targeted to Reduce Cvd
• The Global Burden of Cardiovascular Disease
• 2030 Global Burden of Cardiovascular Disease
• The Global Economic Burden of Cardiovascular Disease
• Sales Performance of Major Drugs in 2022

Chapter 4 Global Market for Anticoagulant Drugs

• Overview
• Products
• Low Molecular Weight Heparin
• Oral Anticoagulants (Vitamin K Antagonists)
• Global Anticoagulant Drugs Market Forecast

Chapter 5 Global Market for Antiplatelet Drugs

• Overview
• Products
• Oral Antiplatelets
• Global Antiplatelet Drugs Market Forecast

Chapter 6 Global Market for Thrombin Inhibitors

• Overview
• Products
• Direct Thrombin Inhibitors
• Thrombolytic Agents
• Direct Factor Xa Inhibitors
• Global Thrombin Inhibitors Market Forecast

Chapter 7 Global Market for Antithrombotic/Anticoagulant Drugs by Region

• Overview
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 8 Sustainability in the Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective

• Introduction to ESG
• Sustainability in Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective
• Key ESG Issues
• Consumer Attitudes Towards ESG
• Industry ESG Performance Analysis
• Case Study
• Concluding Remarks

Chapter 9 Clinical Trials and Patent Landscape

• Clinical Trials Analysis
• Patent Analysis
• Patent by Assignee

Chapter 10 M&A and Venture Funding Outlook

Chapter 11 Competitive Landscape

Chapter 12 Company Profiles

Chapter 13 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/h0sats

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets